Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan 28;14(1):e234876.
doi: 10.1136/bcr-2020-234876.

Hyperthermic intraperitoneal chemotherapy (HIPEC) as another treatment modality for desmoplastic round cell tumour patients: first paediatric experience from UK

Affiliations
Case Reports

Hyperthermic intraperitoneal chemotherapy (HIPEC) as another treatment modality for desmoplastic round cell tumour patients: first paediatric experience from UK

Tomas Sjoberg Bexelius et al. BMJ Case Rep. .

Abstract

We present the first young paediatric patient with desmoplastic small round cell tumour (DSRCT) treated in UK with hyperthermic intraperitoneal chemotherapy (HIPEC). A 7-year-old girl was diagnosed with abdominal DSRCT with peritoneal and liver metastases. After six cycles of chemotherapy she obtained a partial response, including almost complete resolution of the two liver metastases. It was decided to pursue cytoreductive surgery (CRS) combined with HIPEC, a procedure commonly performed in adults, but seldom in a child. The surgery was macroscopically complete and the HIPEC uncomplicated. She continued treatment without delays, including whole abdomino-pelvic radiotherapy and maintenance chemotherapy (cyclophosphamide/vinorelbine for 12 months). She is currently in complete remission 4 months after end of treatment and 26 months after diagnosis. HIPEC was made possible by successful collaboration between multiple teams. CRS-HIPEC proved to be safe and feasible and could be offered to other children with diagnoses of peritoneal malignancies across the UK.

Keywords: malignant disease and immunosuppression; paediatric oncology; paediatrics (drugs and medicines).

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
MRI at presentation.
Figure 2
Figure 2
Five months since diagnosis: partial response.
Figure 3
Figure 3
Eight months since diagnosis, prior to surgery and hyperthermic intraperitoneal chemotherapy.
Figure 4
Figure 4
Thirty days post surgery and hyperthermic intraperitoneal chemotherapy. Complete remission.
Figure 5
Figure 5
Flow sheet of received treatment. DSRCT, desmoplasticsmallroundcelltumour;HIPEC, hyperthermic intraperitoneal chemotherapy.

Similar articles

Cited by

References

    1. Crombleholme TM, Harris BH, Jacir NN, et al. . The desmoplastic round cell tumor: a new solid tumor of childhood. J Pediatr Surg 1993;28:1023–5. 10.1016/0022-3468(93)90508-I - DOI - PubMed
    1. Wong HH, Hatcher HM, Benson C, et al. . Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature. Clin Sarcoma Res 2013;3:14. 10.1186/2045-3329-3-14 - DOI - PMC - PubMed
    1. Lee SB, Kolquist KA, Nichols K, et al. . The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet 1997;17:309–13. 10.1038/ng1197-309 - DOI - PubMed
    1. Bent MA, Padilla BE, Goldsby RE, et al. . Clinical characteristics and outcomes of pediatric patients with desmoplastic small round cell tumor. Rare Tumors 2016;8:24–6. 10.4081/rt.2016.6145 - DOI - PMC - PubMed
    1. Honoré C, Delhorme JB, Nassif E, et al. . Can we cure patients with abdominal desmoplastic small round cell tumor? results of a retrospective multicentric study on 100 patients. Surg Oncol 2019;29:107–12. 10.1016/j.suronc.2019.04.002 - DOI - PubMed

Publication types

MeSH terms